About: http://data.cimple.eu/news-article/4049429a8ba15757be649deeee7ddcdc0856d78e64d83042d9223fde

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/4049429a8ba15757be649deeee7ddcdc0856d78e64d83042d9223fde Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Swiss pharma giant Roche said Monday it would pay $1.8 billion (1.5 billion euros) to buy US firm GenMark Diagnostics and thus broaden its rapid test portfolio, including for Covid-19. The Swiss company said it had signed a "definitive merger agreement" with the California-based firm after both boards approved the all-cash deal. Roche is offering $24.05 a share for GenMark, a premium of some 43 percent to its last quoted share price on February 10. GenMark makes molecular tests that can establish the presence of several different pathogens from just one sample, Monday's statement said. "Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio," Roche chief Thomas Schinecker said in the statement. The deal, subject to regulatory approval, should be concluded in the second quarter, the company said. GenMark says its so-called syndromic panel tests can quickly identify the most common viral and bacterial organisms linked to upper respiratory infection, including SARS-CoV-2, the virus that causes Covid-19. The current pandemic, which has killed some 2.65 million people worldwide since the first cases were detected in China in late 2019, has spurred huge demand for rapid tests. Roche, the world's top cancer drug maker, already counts a large number of various tests for the virus, but said testing using the GenMark respiratory pathogen panels would be a welcome compliment to its existing portfolio. The tests were also useful for "the rapid identification of bloodstream infections and the detection of antimicrobial resistance genes, (which) are more essential than ever for hospitals and their patients," Schinecker said. Analysts hailed the deal. "Today's acquisition makes sense as it adds a novel testing technology that is modular and scalable," Vontobel analyst Stefan Scheider said in a research note. With the addition of GenMark, he said, Roche's diagnostics unit should see growth "for 2021 and beyond significantly accelerate." Following the news, Roche' share price rose 1.2 percent in late-morning trading to 320.60 Swiss francs a piece, while the Swiss stock exchange's main SMI index was up 0.48 percent. noo/nl/bmm
schema:headline	Roche to buy Covid test maker GenMark Diagnostics for $1.8 bn
schema:mentions	Antimicrobial resistance Upper respiratory tract infection Pathogen Hoffmann-La Roche Applied Digital Data Systems Clarence Thomas Switzerland Cancer Pandemic Virus Coronavirus disease China Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Vontobel Molecular diagnostics Rapid influenza diagnostic test Stefan the First-Crowned Mark Roebuck
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	69 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software